FDA's Increased Focus on Advertising Regulation and Enforcement for argenx

On January 30, 2026, the U.S. Food and Drug Administration (FDA), through its Office of Prescription Drug Promotion (OPDP), issued two Untitled Letters to argenx SE (ticker: ARGX) concerning direct-to-consumer (DTC) television advertisements for Vyvgart Hytrulo (active ingredient: efgartigimod alfa/hyaluronidase-qvfc), a treatment for autoimmune diseases. This action aligns with the FDA's strengthened marketing regulation and enforcement approach, which began in September 2025, and represents a significant example of the agency's increasingly stringent review criteria for pharmaceutical advertising. The agency is undertaking a comprehensive crackdown to prevent inappropriate depictions of a drug's efficacy and ease of administration in commercial materials that directly impact patient decision-making. In contrast to the regulatory authorities' relatively moderate stance in the past, they are now demonstrating a clear intention to establish market order by proactively imposing sanctions across digital media and broadcast advertising.

Concerns Regarding Exaggerated Efficacy and Misleading Information on Administration

The advertisements in question depicted patients with chronic inflammatory demyelinating polyneuropathy (CIDP) engaging in strenuous physical activities such as playing golf or driving after receiving the medication, which sparked controversy. The FDA determined that such depictions could mislead patients into believing that they would be completely free from physical limitations after treatment. Furthermore, the agency noted that the visual representation of convenient self-administration in a busy daily routine oversimplified the detailed instructions for subcutaneous injection and the potential risks of adverse effects. Marketing that emphasizes only the convenience of the drug while obscuring the safety precautions and significant adverse effects that patients should be aware of is subject to immediate corrective action by the regulatory authorities.

Impact on Sales of a Blockbuster Drug and the Competitive Landscape

The Vyvgart product line is a key blockbuster asset for argenx, generating global net sales of $4.2 billion in 2025 and $1.3 billion in the first quarter of 2026, demonstrating continued growth. In particular, Vyvgart Hytrulo, the subcutaneous injection formulation with improved convenience, is competing with AstraZeneca's Ultomiris (active ingredient: ravulizumab) and UCB's Rystiggo (active ingredient: rozanolixizumab) for market share in the generalized myasthenia gravis (gMG) field. The receipt of this regulatory letter at a critical juncture, as the drug seeks to replace the established intravenous immunoglobulin (IVIG) standard of care in the CIDP market, necessitates a revision of the marketing strategy. While there are short-term concerns about the cost of replacing advertisements and the potential slowdown in marketing momentum, the company's ability to respond quickly to the regulatory issues will be a key factor in determining its future market competitiveness.

Strengthening Internal Compliance within the Biopharmaceutical Industry

Recently, the FDA has expanded its regulatory oversight by issuing Untitled Letters to major pharmaceutical companies, including argenx, Pfizer (Adcetris), Bayer (Nubeqa), and Axsome Therapeutics (Auvelity). This underscores the importance of thoroughly managing post-market compliance, in addition to new drug development and approval, in order to protect corporate value. The pharmaceutical industry must proactively control regulatory risks by applying objective depictions based on clinical data and strict risk disclosure standards from the advertising creation stage. Investors should also focus on the company's ability to collaborate with regulatory authorities to resolve risks quickly, as demonstrated by Bayer's successful resolution of a similar issue, rather than simply focusing on the receipt of a warning letter.